The "Kick" Revisited in the "Kick and Kill" Strategy

“踢杀”策略中的“踢”重温

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Although combination antiretroviral therapy (cART) can reduce plasma HIV RNA levels in most infected individuals to below the detection limit of clinical assays, it is not curative and persistent viremia is detected in the majority of patients.A rare, but extremely stable, HIV proviral DNA reservoir in resting CD4+ T cells (i.e. the latent reservoir) is thought to be the major source of persistent viremia. This latent reservoir can produce infectious virus when the host cell is reactivated by recall antigen (or by various cytokines), that can reseed HIV infection if cART is discontinued. Eradication of the latent reservoir may lead to a cure for HIV infection. Currently, a "kick and kill" strategy is being testd in ongoing clinical trials as a pharmacological approach to deplete the latent HIV reservoir. This strategy involves the administration of a latency reversing agent (LRA) which induces HIV out of latency (the "kick"), that in turn facilitates death of the infected cells by viral cytopathic effets (the "kill"). Several distinct therapeutic classes of LRAs have been identified that effectively "kick" HIV out of latency. In contrast, our understanding of the "kill" in HIV-infected resting CD4 T cells is extremely limited. The primary goal of this study is to comprehensively assess the "kill in the "kick and kill" strategy, using novel primary cell models of latency in highly purified naïe (TN) and central memory (TCM) CD4+ T cells. Collectively, we anticipate that these studies will yield important insights into HIV persistence, and may have the potential to identify new targets or approaches to eradicate latent HIV infection. Furthermore, they could help explain clinical finding from ongoing trials that are focused on depleting the latent HIV reservoir.
 描述(申请人提供):尽管联合抗逆转录病毒疗法(cART)可以将大多数感染个体中的血浆HIV RNA水平降低至低于临床测定的检测限,但它不是治愈性的,并且在大多数患者中检测到持续的病毒血症。静止CD4+ T细胞中的HIV前病毒DNA储库(即潜伏储库)被认为是持续性病毒血症的主要来源。当宿主细胞被召回抗原(或各种细胞因子)重新激活时,这种潜伏的储存库可以产生感染性病毒,如果cART中断,则可以重新接种HIV感染。根除潜伏的宿主可能导致治愈艾滋病毒感染。目前,正在进行的临床试验正在测试一种“踢杀”策略,作为一种耗尽潜伏的艾滋病毒储存库的药理学方法。该策略涉及施用潜伏期逆转剂(LRA),其诱导HIV脱离潜伏期(“踢”),这进而通过病毒致细胞病变效应促进受感染细胞的死亡(“杀死”)。已经确定了几种不同的LRA治疗类别,它们可以有效地将HIV“踢出”潜伏期。相比之下,我们对HIV感染的静息CD4 T细胞中的“杀伤”的理解非常有限。本研究的主要目标是使用高度纯化的naïe(TN)和中央记忆(TCM)CD4+ T细胞中潜伏期的新原代细胞模型,全面评估“踢杀”策略中的“杀死”。总的来说,我们预计这些研究将产生重要的见解艾滋病毒的持久性,并可能有潜力确定新的目标或方法,以消除潜伏的艾滋病毒感染。此外,它们可以帮助解释正在进行的试验中的临床发现,这些试验的重点是消除潜伏的HIV储存库。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NICOLAS PAUL SLUIS-CREMER其他文献

NICOLAS PAUL SLUIS-CREMER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NICOLAS PAUL SLUIS-CREMER', 18)}}的其他基金

Elucidating the role of B cell mediated trans infection in the establishment of the latent HIV-1 reservoir
阐明 B 细胞介导的反式感染在潜伏 HIV-1 病毒库建立中的作用
  • 批准号:
    10675438
  • 财政年份:
    2022
  • 资助金额:
    $ 18.62万
  • 项目类别:
Elucidating the role of B cell mediated trans infection in the establishment of the latent HIV-1 reservoir
阐明 B 细胞介导的反式感染在潜伏 HIV-1 病毒库建立中的作用
  • 批准号:
    10402053
  • 财政年份:
    2022
  • 资助金额:
    $ 18.62万
  • 项目类别:
Potent inhibition of HIV-1 latency reversal by PF 03758309
PF 03758309 有效抑制 HIV-1 潜伏期逆转
  • 批准号:
    10409846
  • 财政年份:
    2021
  • 资助金额:
    $ 18.62万
  • 项目类别:
Potent inhibition of HIV-1 latency reversal by PF 03758309
PF 03758309 有效抑制 HIV-1 潜伏期逆转
  • 批准号:
    10326435
  • 财政年份:
    2021
  • 资助金额:
    $ 18.62万
  • 项目类别:
The "Kick" Revisited in the "Kick and Kill" Strategy
“踢杀”策略中的“踢”重温
  • 批准号:
    9016996
  • 财政年份:
    2016
  • 资助金额:
    $ 18.62万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    8143220
  • 财政年份:
    2010
  • 资助金额:
    $ 18.62万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    9265402
  • 财政年份:
    2009
  • 资助金额:
    $ 18.62万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    7872929
  • 财政年份:
    2009
  • 资助金额:
    $ 18.62万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    8079113
  • 财政年份:
    2009
  • 资助金额:
    $ 18.62万
  • 项目类别:
Novel mechanisms of HIV resistance to RTIs
HIV对RTIs耐药的新机制
  • 批准号:
    8289671
  • 财政年份:
    2009
  • 资助金额:
    $ 18.62万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.62万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了